What’s New

Bristol-Myers Squibb’s Opdivo ® (nivolumab) + Low- Dose Yervoy ® (ipilimumab) is the First Immuno-Oncology Combination Approved for MSI-H/dMMR mCRC Patients Who Progressed Following Treatment with a Fluoropyrimidine, Oxaliplatin and Irinotecan

Read the press release


EVENTS

View All Events